Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1957 Target Snapshot

Insulin-like growth factor 1 receptor · SINGLE PROTEIN · Homo sapiens

5,790Compounds
1,076Assays
11Approved Drugs
5,905.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Insulin-like growth factor 1 receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 13 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P08069. Start with neoplasm, then reuse UniProt P08069 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt P08069 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 13 linked drugs
Open source guide
Disease program
neoplasm

Insulin-like growth factor 1 receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 13 linked drugs remain visible in the same block.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include AXL-1717, BIIB-022, BMS-754807, CIXUTUMUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 13 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Insulin-like growth factor 1 receptor as ChEMBL target CHEMBL1957, mapped to UniProt P08069. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Insulin-like growth factor 1 receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1957
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08069
Insulin-like growth factor 1 receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Insulin-like growth factor 1 receptor is the right protein anchor across sources, using UniProt P08069 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as approved-linked support. It currently carries 13 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelInsulin-like growth factor 1 receptor
UniProt AccessionP08069
Component TypeProtein
Sequence Length1367 aa

Insulin-like growth factor 1 receptor

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Insulin-like growth factor 1 receptor, mapped to UniProt P08069. Sequence length is 1367 aa.

Mapped IDP08069
Review nameInsulin-like growth factor 1 receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Insulin-like growth factor 1 receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
neoplasm
13 linked drugs · 13 direct · 13 efficacy
Linked drugAXL-1717
Linked drugBIIB-022
Linked drugBMS-754807
Linked drugCIXUTUMUMAB
Approved-linked Approved
Graves ophthalmopathy
2 linked drugs · 2 direct · 2 efficacy
Linked drugTEPROTUMUMAB
Linked drugVELIGROTUG
Approved-linked Approved
Laron syndrome
2 linked drugs · 2 direct · 2 efficacy
Linked drugMECASERMIN
Linked drugMECASERMIN RINFABATE
Approved-linked Approved
Growth delay
1 linked drug · 1 direct · 1 efficacy
Linked drugMECASERMIN
Approved-linked Approved
growth hormone insensitivity syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugMECASERMIN
Approved-linked Approved
hypothyroidism
1 linked drug · 1 direct · 1 efficacy
Linked drugMECASERMIN
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include AXL-1717, BIIB-022, BMS-754807, CIXUTUMUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

11
Approved
4
Phase III
11
Phase II
10
Phase I
Assay Mix

Activity Type Distribution

IC504,597.0
KI904.0
EC5012.0
KD392.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3950012 10.3 IC50 0.05 Preclinical
CHEMBL3905758 10.3 IC50 0.05 Preclinical
CHEMBL3979064 10.1 IC50 0.08 Preclinical
CHEMBL3977170 10.1 IC50 0.08 Preclinical
CHEMBL3955626 10.1 IC50 0.08 Preclinical
CHEMBL3928243 10.1 IC50 0.08 Preclinical
CHEMBL3979509 10.05 IC50 0.09 Preclinical
CHEMBL3969930 10.05 IC50 0.09 Preclinical
CHEMBL3896205 10.05 IC50 0.09 Preclinical
CHEMBL3892425 10.0 IC50 0.1 Preclinical
Distribution

pChEMBL Value Distribution

192
5.0
265
5.5
721
6.0
393
6.5
818
7.0
366
7.5
260
8.0
141
8.5
167
9.0
91
9.5
pChEMBL
Approved Drugs

Approved Drugs

ENTRECTINIB
CHEMBL1983268
Approved 2019
BRIGATINIB
CHEMBL3545311
Approved 2017
CERITINIB
CHEMBL2403108
Approved 2014
NINTEDANIB
CHEMBL502835
Approved 2014
CRIZOTINIB
CHEMBL601719
Approved 2011
Assay Landscape

Assay Landscape

1,076
Total Assays
2,740
Tested Compounds
3
Assay Types
Binding — 1,022 assays, 2,740 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 753 1,584 7.3
cell-based format 170 579 6.7
assay format 89 568 6.9
subcellular format 8 8 5.9
cell-free format 2 1 6.3
Functional — 53 assays, 136 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 47 17 6.7
assay format 6 119 6.3
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine